ArticleAmerican journal of translational research2025
Edaravone dextrocamphorol combined with intravenous thrombolysis enhances recovery in acute ischemic stroke.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effect of edaravone dextrocamphorol on neurotrophic status and functional recovery in patients undergoing intravenous thrombolysis for acute ischemic stroke.
methodsThis single-center retrospective study enrolled 100 patients with acute ischemic stroke. Patients were divided into two groups: the observation group (n = 45), who received both intravenous alteplase and edaravone dextrocamphorol treatment, and the control group (n = 55), who received intravenous thrombolysis with alteplase alone. Clinical indicators that were compared between groups included baseline characteristics, NIHSS scores, nutritional status (albumin, hemoglobin, prealbumin, and transferrin), diet satisfaction, and quality of life (SF-36), and negative psychological symptoms.
resultsCompared to the control group, the observation group demonstrated significantly higher diet satisfaction, improved dietary-related symptoms, and better neurological function recovery (all P < 0.05). SF-36 scores, including psychological, material, and total functional domains, were also superior in the observation group (P < 0.05 for all). Additionally, nutritional status and negative psychological symptoms (P < 0.05) improved significantly in the observation group.
conclusionEdaravone dextrocamphorol, when added to intravenous thrombolysis, significantly enhances recovery in acute ischemic stroke. This strategy improves diet satisfaction, neurological function, quality of life, nutritional status, and psychological well-being.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.